Why Roivant Sciences Stock is Trading Higher Today

Roivant Sciences Ltd ROIV released results from the chronic period of the TUSCANY-2 Phase 2b study of RVT-3101 in adult patients with moderate to severe ulcerative colitis.

The company says this is the first-ever long-duration data reported for an anti-TL1A antibody.

Also Read: Roivant Sciences Highlights Topline Data From Atopic Dermatitis Drug In Patients As Young As 2 Years.

Key efficacy analyses from the induction period were measured at week 14, while outcomes for the chronic period were measured at week 56.

For all patients receiving the expected Phase 3 dose in both periods:

  • 36% achieved clinical remission at week 56 (compared with 29% at week 14).
  • 50% showed endoscopic improvement at week 56 (compared with 36% at week 14).
  • 21% achieved endoscopic remission at week 56 (compared with 11% at week 14).

For patients with a prespecified biomarker receiving the expected Phase 3 dose in both periods:

  • 43% achieved clinical remission at week 56 vs. 33%.
  • 64% showed endoscopic improvement vs. 47%.
  • 36% achieved endoscopic remission vs. 13%.

RVT-3101 demonstrated sustained efficacy across a broad dose range measured at 56 weeks. It was well-tolerated with no impact of immunogenicity on clinical efficacy or safety results.

Price Action: ROIV shares are up 13.00% at 10.76 on the last check Thursday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...